Humulin R

Humulin R is a recombinant human insulin (rDNA) supplied as an injectable solution for subcutaneous administration. It contains insulin human as the active ingredient and is marketed in the European Union as a prescription product. The formulation provides rapid‑acting insulin to replace or supplement endogenous insulin in patients with diabetes. Humulin R is intended for use under medical supervision to help control blood glucose levels.

Humulin R is indicated for the management of hyperglycemia in adults and children with diabetes mellitus. It is used to provide basal and mealtime insulin coverage in both type 1 and type 2 diabetes. - Initiation of insulin therapy in newly diagnosed type 1 diabetes. - Supplemental insulin for type 2 diabetes when oral agents are insufficient. - Adjustment of insulin doses around meals to control post‑prandial glucose. - Management of hyperglycemia during illness, stress, or steroid therapy. - Use in insulin pump therapy as a rapid‑acting component.

Adverse reactions to Humulin R may vary in frequency and severity; they are typically categorized as common or serious.

Common: - Mild hypoglycemia, especially if meals are delayed or doses are high. - Injection site reactions such as redness, swelling, or itching. - Lipodystrophy presenting as localized fat loss or accumulation. - Transient weight gain due to fluid retention. - Nausea or mild abdominal discomfort. - Headache or dizziness without hypoglycemia.

Serious: - Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness). - Allergic reactions ranging from urticaria to anaphylaxis. - Persistent hyperglycemia indicating possible insulin resistance or dosing error. - Edema or heart failure exacerbation in susceptible patients. - Hypersensitivity leading to serum sickness‑like reaction.

When prescribing or using Humulin R, clinicians and patients should consider several precautionary measures to minimize risks and ensure optimal glycemic control. - Adjust dose during periods of reduced food intake, increased physical activity, or illness. - Monitor blood glucose frequently, especially when initiating therapy or changing dose. - Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced. - Assess for signs of hypoglycemia in elderly or cognitively impaired individuals. - Evaluate cardiovascular status, since rapid‑acting insulin can affect fluid balance. - Avoid use during pregnancy unless benefits outweigh potential risks, and follow obstetric guidance.

Humulin R may interact with other medicines that affect glucose metabolism, insulin sensitivity, or cardiovascular function, requiring dose adjustments or monitoring.

Avoid: - Concurrent administration of other rapid‑acting insulins without appropriate dose reduction. - Use with beta‑blockers in patients prone to hypoglycemia, as they may mask symptoms. - Combination with high‑dose corticosteroids that markedly raise blood glucose.

Use with caution: - Sulfonylureas or meglitinides, which increase hypoglycemia risk. - ACE inhibitors or ARBs in patients with renal impairment, as insulin clearance may change. - Alcohol consumption, which can potentiate hypoglycemia, especially when meals are skipped.